Phase II double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of H1/IC31 (trademarked), an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells per mm cubed

Trial Profile

Phase II double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of H1/IC31 (trademarked), an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells per mm cubed

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2016

At a glance

  • Drugs H1IC (Primary)
  • Indications Tuberculosis
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Statens Serum Institut
  • Most Recent Events

    • 14 Nov 2012 Status changed from recruiting to completed as reported by Pan-African Clinical Trials Registry.
    • 11 Jan 2012 Status changed from not yet recruiting to recruiting, according to an Intercell media release.
    • 11 Jan 2012 First results from this trial are expected in 2013, according to an Intercell media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top